Full Text Journal Articles by
Author Baba Psalm Duniya Inusa

Advertisement

Find full text journal articles








Racial inequalities in access to care for young people living with pain due to sickle cell disease.

Baba Psalm Duniya Inusa, Eufemia Jacob, Livingstone Dogara, Kofi A Anie,

Lancet Child Adolesc Health (The Lancet. Child & adolescent health)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Paediatric to adult transition care for patients with sickle cell disease: a global perspective.

Baba Psalm Duniya Inusa, Claire Elizabeth Stewart, Shamarah Mathurin-Charles, Jerlym Porter, Lewis Li-Yen Hsu, Wale Atoyebi, Mariane De Montalembert, Ijeoma Diaku-Akinwumi, Norah O Akinola, Biree Andemariam, Miguel Raul Abboud, Marsha Treadwell,

Sickle cell disease is a life-threatening inherited condition designated as a public health priority by WHO. Increased longevity of patients with sickle cell disease in high-income, middle-income, and low-income countries present unprecedented challenges for all settings; however, a globally standardised solution for patient transition from paediatric to adult sickle cell ... Read more >>

Lancet Haematol (The Lancet. Haematology)
[2020, 7(4):e329-e341]

Cited: 0 times

View full text PDF listing >>



Advertisement

Geographic Differences in Phenotype and Treatment of Children with Sickle Cell Anemia from the Multinational DOVE Study.

Baba Psalm Duniya Inusa, Raffaella Colombatti, David C Rees, Matthew M Heeney, Carolyn C Hoppe, Bernhards Ogutu, Hoda M Hassab, Chunmei Zhou, Suqin Yao, Patricia B Brown, Lori E Heath, Joseph A Jakubowski, Miguel R Abboud,

BACKGROUND:DOVE (Determining Effects of Platelet Inhibition on Vaso-Occlusive Events) was a Phase 3, randomized, double-blind, placebo-controlled study conducted in children with sickle cell anemia at 51 sites in 13 countries across four continents. PROCEDURE:Data from DOVE were assessed for regional differences in subject phenotype and treatment. Demographics, baseline clinical and ... Read more >>

J Clin Med (Journal of clinical medicine)
[2019, 8(11):]

Cited: 0 times

View full text PDF listing >>



Low-dose hydroxycarbamide therapy may offer similar benefit as maximum tolerated dose for children and young adults with sickle cell disease in low-middle-income settings.

Baba Psalm Duniya Inusa, Atoyebi Wale, Abdul Aziz Hassan, Tushar Idhate, Livingstone Dogara, Ifeoma Ijei, Yewen Qin, Kofi Anie, Juliana Olufunke Lawson, Lewis Hsu,

The multiple clinical benefits of hydroxycarbamide in sickle cell disease are supported by a large body of evidence. The maximum tolerated dose (MTD) is the regimen recommended by guidelines from a panel of National Heart, Lung, and Blood Institute (NHLBI) experts, but other dosage regimens have been used in babies ... Read more >>

F1000Res (F1000Research)
[2018, 7:]

Cited: 0 times

View full text PDF listing >>



Low-dose hydroxycarbamide therapy may offer similar benefit as maximum tolerated dose for children and young adults with sickle cell disease in low-middle-income settings

Baba Psalm Duniya Inusa, Wale Atoyebi, Abdul Aziz Hassan, Tushar Idhate, Livingstone Dogara, Ifeoma Ijei, Yewen Qin, Kofi Anie, Juliana Olufunke Lawson, Lewis Hsu,

The multiple clinical benefits of hydroxycarbamide in sickle cell disease are supported by a large body of evidence. The maximum tolerated dose (MTD) is the regimen recommended by guidelines from a panel of National Heart, Lung, and Blood Institute (NHLBI) experts, but other dosage regimens have been used in babies ... Read more >>

()
[, :]

Cited: 1 time

View full text PDF listing >>





Advertisement

Disclaimer
0.5673 s